Advertisement

Treatment

  • Marinko Marušić
  • Rosana Troskot Perić
  • Nikolina Tolj Karaula
Chapter
Part of the Clinical Gastroenterology book series (CG)

Abstract

The management of enteropathy in diabetes represents a challenge today and often requires a multidisciplinary approach. Current therapies are mostly symptomatic, suboptimal, and in some cases ineffective (Ördög et al., Minerva gastroenterologica e dietologica 55:315–43, 2009; Maisey, Diabetes Ther 7:379–86, 2016). Diarrhea is a less common gastrointestinal abnormality than constipation in patients with diabetes, but it is clinically more relevant and troubling (Sellin and Chang, Nat Clin Pract Gastroenterol Hepatol 5:162–71, 2008). The management of patients with diabetic diarrhea should focus on general supportive measures, symptomatic treatment, and treatment of underlying cause. Constipation is one of the most common gastrointestinal complication in patients with diabetes. There is no specific therapy for diabetes-related constipation, and the majority of patients are treated in the same way as patients with idiopathic chronic constipation (Sellin and Chang, Nat Clin Pract Gastroenterol Hepatol 5:162–71, 2008). Better glycemic control may be of some benefit, but the overall management is challenging (Attaluri et al., Aliment Pharmacol Ther 33:822–8, 2011). Fecal incontinence is a common gastrointestinal complication of patients with diabetes, but infrequently reported. The management of fecal incontinence in diabetes includes supportive care, medical therapy, behavioral measures, and more invasive surgical options.

Keywords

Diabetic enteropathy Intestinal dysfunction Diarrhea Fecal incontinence Constipation Diabetes Gastrointestinal abnormalities 

References

  1. 1.
    Ördög T, Hayashi Y, Gibbons SJ. Cellular pathogenesis of diabetic gastroenteropathy. Minerva Gastroenterol Dietol. 2009;55(3):315–43.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Sellin JH, Chang EB. Therapy insight: gastrointestinal complications of diabetes pathophysiology and management. Nat Clin Pract Gastroenterol Hepatol. 2008;5(3):162–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26(5):611–24.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Azpiroz F, Malagelada C. Diabetic neuropathy in the gut: pathogenesis and diagnosis. Diabetologia. 2016;59(3):404–8.CrossRefGoogle Scholar
  5. 5.
    Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24(2):371–81.CrossRefGoogle Scholar
  6. 6.
    Maisey A. A practical approach to gastrointestinal complications of diabetes. Diabetes Therapy. 2016;7(3):379–86.  https://doi.org/10.1007/s13300-016-0182-y.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes Mellitus. A population-based survey of 15000 adults. Arch Intern Med. 2001;161(16):1989–96.CrossRefGoogle Scholar
  8. 8.
    Bharucha AE. Fecal incontinence. Gastroenterology. 2003;124(6):1672–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013;4(3):51–63.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lysy J, Israeli E, Goldin E. The prevalence of chronic diarrhea among diabetic patients. Am J Gastroenterol. 1999;94(8):2165–70.CrossRefGoogle Scholar
  11. 11.
    Consoli A, Formoso G. Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opin Drug Saf. 2015;14(2):207–18.CrossRefPubMedGoogle Scholar
  12. 12.
    Fenofibrate 267mg capsules—summary of product characteristics. http://www.medicine.org.uk/emc/medicine/22425/SPC. Accessed July 2017
  13. 13.
    Bytzer P, Talley NJ, Jones MP, Horowitz M. Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus. Aliment Pharmacol Ther. 2001;15(1):137–42.CrossRefGoogle Scholar
  14. 14.
    Badiga MS, Jain NK, Casanova C, Pitchumoni CS. Diarrhea in diabetics: the role of sorbitol. J Am Coll Nutr. 1990;9(6):578–82.CrossRefGoogle Scholar
  15. 15.
    Shakil A, Church RJ, Rao SS. Gastrointestinal complications of diabetes. Am Fam Physician. 2008;77(12):1697–702.PubMedGoogle Scholar
  16. 16.
    Fedorak R, Field M. Antidiarrheal therapy. Prospects for new agents. Dig Dis Sci. 1987;32:195–205.CrossRefPubMedGoogle Scholar
  17. 17.
    Bretzke G. Therapy of diarrhea in diabetic enteropathy with clonidine. Z Gesamte Inn Med. 1987;42:680–2.PubMedGoogle Scholar
  18. 18.
    Morali G, Braverman D, Lissi J, Goldstein R, Jacobsohn W. Effect of clonidine on gallbladder contraction and small bowel transit time in insulin-treated diabetics. Am J Gastroenterol. 1991;86:995–9.PubMedGoogle Scholar
  19. 19.
    Bharucha A, Fletcher J, Camilleri M, Edge J, Carlson P, Zinsmeister A. Effects of clonidine in women with fecal incontinence. Clin Gastroenterol Hepatol. 2014;12(5):843–51.e842; quiz e44.Google Scholar
  20. 20.
    Sacerdote A. Topical clonidine for diabetic diarrhea. Ann Intern Med. 1986;105:139.CrossRefPubMedGoogle Scholar
  21. 21.
    Roof L. Treatment of diabetic diarrhea with clonidine. Am J Med. 1987;83:603–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Migliore A, Barone C, Manna R, Greco A. Diabetic diarrhea and clonidine. Ann Intern Med. 1988;109:170–1.CrossRefPubMedGoogle Scholar
  23. 23.
    Fragkos KC, Zárate-Lopez N, Frangos CC. What about clonidine for diarrhoea? A systematic review and meta-analysis of its effect in humans. Ther Adv Gastroenterol. 2016;9(3):282–301.CrossRefGoogle Scholar
  24. 24.
    Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 1991;325(21):1461–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Dudl RJ, Anderson DS, Forsythe AB, Ziegler MG, O’Dorisio TM. Treatment of diabetic diarrhea and orthostatic hypotension with somatostatin analogue SMS 201-995. Am J Med. 1987;83(3):584–8.Google Scholar
  26. 26.
    Mourad FH, Gorard D, Thillainayagam AV, Colin-Jones D, Farthing MJ. Effective treatment of diabetic diarrhoea with somatostatin analogue, octreotide. Gut. 1992;33(11):1578–80.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Walker JJ, Kaplan DS. Efficacy of the somatostatin analog octreotide in the treatment of two patients with refractory diabetic diarrhea. Am J Gastroenterol. 1993;88(5):765–7.PubMedGoogle Scholar
  28. 28.
    Corbould A, Campbell J. Efficacy of octreotide but not long-acting somatostatin analogue for severe refractory diabetic diarrhea. Diabet Med. 2009;26(8):828–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Pimentel M. Review of rifaximin as treatment for SIBO and IBS. Expert Opin Investig Drugs. 2009;18:349–58.CrossRefGoogle Scholar
  30. 30.
    Gerard L, Garey KW, DuPont HL. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti-Infect Ther. 2005;3:201–11.CrossRefPubMedGoogle Scholar
  31. 31.
    Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity—a review. Chemotherapy. 2005;51(Suppl 1):67–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Maleki D, Camilleri M, Burton DD, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci. 1998;43(11):2373–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS. Randomised clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther. 2011;33(7):822–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. Gastroenterology. 2013;144(1):218–38.  https://doi.org/10.1053/j.gastro.2012.10.028.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Müller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232–42.CrossRefPubMedGoogle Scholar
  37. 37.
    Wald A. Is chronic use of stimulant laxatives harmful to the colon? J Clin Gastroenterol. 2003;36(5):386–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010;7:CD007570.Google Scholar
  39. 39.
    Emmanuel A, Mattace-Raso F, Neri MC, Petersen KU, Rey E, Rogers J. Constipation in older people: a consensus statement. Int J Clin Pract 2017;71(1).Google Scholar
  40. 40.
    Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther. 2007;26(1):9–20.CrossRefPubMedGoogle Scholar
  41. 41.
    Enck P. Biofeedback training in disordered defecation: a critical review. Dig Dis Sci. 1993;38:1953–60.CrossRefPubMedGoogle Scholar
  42. 42.
    Bassotti G, Chistolini F, Sietchiping-Nzepa F, de Roberto G, Morelli A, Chiarioni G. Biofeedback for pelvic floor dysfunction in constipation. BMJ. Br Med J. 2004;328(7436):393–6.CrossRefGoogle Scholar
  43. 43.
    Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365(6):527–36.CrossRefPubMedGoogle Scholar
  44. 44.
    Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25(11):1351–61.CrossRefPubMedGoogle Scholar
  45. 45.
    Lang L. The Food and Drug Administration approves lubiprostone for irritable bowel syndrome with constipation. Gastroenterology. 2008;135(1):7.PubMedGoogle Scholar
  46. 46.
    Schey R, Rao SSC. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci. 2011;56:1619–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.CrossRefPubMedGoogle Scholar
  48. 48.
    Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–28.CrossRefPubMedGoogle Scholar
  49. 49.
    Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–65.CrossRefPubMedGoogle Scholar
  50. 50.
    Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22:991–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Ford A, Suares N. Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis. Gut. 2011;60:209–18.CrossRefPubMedGoogle Scholar
  52. 52.
    Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.CrossRefPubMedGoogle Scholar
  53. 53.
    Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol. 2007;102:1964–71.CrossRefPubMedGoogle Scholar
  54. 54.
    Wexner SD, Daniel N, Jagelman DG. Colectomy for constipation: physiologic investigation is the key to success. Dis Colon Rectum. 1991;34:851–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Nyam DC, Pemberton JH, Ilstrup DM, Rath DM. Long-term results of surgery for chronic constipation. Dis Colon Rectum. 1997;40:273–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Kamm MA, Dudding TC, Melenhorst J, et al. Sacral nerve stimulation for intractable constipation. Gut. 2010;59:333–40.CrossRefPubMedGoogle Scholar
  57. 57.
    Maeda Y, Lundby L, Buntzen S, Laurberg S. Sacral nerve stimulation for constipation: suboptimal outcome and adverse events. Dis Colon Rectum. 2010;53:995–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006;101:2570–5.CrossRefPubMedGoogle Scholar
  59. 59.
    Faried M, El Nakeeb A, Youssef M, Oman N, El Monem HA. Comparative study between surgical and non-surgical treatment of anismus in patients with symptoms of obstructed defecation: a prospective randomized study. J Gastrointest Surg. 2010;14:1235–43.CrossRefPubMedGoogle Scholar
  60. 60.
    Titu LV, Riyad K, Carter H, Dixon AR. Stapled transanal rectal resection for obstructed defecation: a cautionary tale. Dis Colon Rectum. 2009;52:1716–22.CrossRefPubMedGoogle Scholar
  61. 61.
    Dodi G, Pietroletti R, Milito G, Binda G, Pescatori M. Bleeding, incontinence, pain and constipation after STARR transanal double stapling rectotomy for obstructed defecation. Tech Coloproctol. 2003;7:148–53.CrossRefPubMedGoogle Scholar
  62. 62.
    Corman ML, Carriero A, Hager T, et al. Consensus conference on the stapled transanal rectal resection (STARR) for disordered defaecation. Color Dis. 2006;8:98–101.CrossRefGoogle Scholar
  63. 63.
    Sangwan YP, Coller JA. Fecal incontinence. Surg Clin North Am. 1994;74(6):1377–98.CrossRefPubMedGoogle Scholar
  64. 64.
    Rothbarth J, Bemelman WA, Meijerink WJ, et al. What is the impact of fecal incontinence on quality of life? Dis Colon Rectum. 2001;44(1):67–71.CrossRefPubMedGoogle Scholar
  65. 65.
    Lee D, Arora G. Medical management of fecal incontinence in challenging populations: a review. Clin Colon Rectal Surg. 2014;27(3):91–8.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Bliss DZ, Jung HJ, Savik K, et al. Supplementation with dietary fiber improves fecal incontinence. Nurs Res. 2001;50(4):203–13.CrossRefPubMedGoogle Scholar
  67. 67.
    Lauti M, Scott D, Thompson-Fawcett MW. Fibre supplementation in addition to loperamide for faecal incontinence in adults: a randomized trial. Color Dis. 2008;10(6):553–62.CrossRefGoogle Scholar
  68. 68.
    Sze EH, Hobbs G. Efficacy of methylcellulose and loperamide in managing fecal incontinence. Acta Obstet Gynecol Scand. 2009;88(7):766–71.CrossRefPubMedGoogle Scholar
  69. 69.
    Wald A, Bharucha AE, Cosman BC, Whitehead WE. ACG clinical guideline: management of benign anorectal disorders. Am J Gastroenterol. 2014;109(8):1141–57.CrossRefPubMedGoogle Scholar
  70. 70.
    Ouslander JG, Simmons S, Schnelle J, Uman G, Fingold S. Effects of prompted voiding on fecal continence among nursing home residents. J Am Geriatr Soc. 1996;44(4):424–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Schnelle JF, Leung FW, Rao SS, et al. A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. J Am Geriatr Soc. 2010;58(8):1504–11.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Schnelle JF, Alessi CA, Simmons SF, Al-Samarrai NR, Beck JC, Ouslander JG. Translating clinical research into practice: a randomized controlled trial of exercise and incontinence care with nursing home residents. J Am Geriatr Soc. 2002;50(9):1476–83.CrossRefPubMedGoogle Scholar
  73. 73.
    Cheetham M, Brazzelli M, Norton C, Glazener CM. Drug treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2003;3:CD002116.Google Scholar
  74. 74.
    Ehrenpreis ED, Chang D, Eichenwald E. Pharmacotherapy for fecal incontinence: a review. Dis Colon Rectum. 2007;50(5):641–9.CrossRefPubMedGoogle Scholar
  75. 75.
    Schiller LR, Santa Ana CA, Morawski SG, Fordtran JS. Mechanism of the antidiarrheal effect of loperamide. Gastroenterology. 1984;86(6):1475–80.PubMedGoogle Scholar
  76. 76.
    Regnard C, Twycross R, Mihalyo M, Wilcock A. Loperamide. J Pain Symptom Manag. 2011;42(2):319–23.CrossRefGoogle Scholar
  77. 77.
    Palmer KR, Corbett CL, Holdsworth CD. Double-blind cross-over study comparing loperamide, codeine and diphenoxylate in the treatment of chronic diarrhea. Gastroenterology. 1980;79(6):1272–5.PubMedGoogle Scholar
  78. 78.
    Wald A, Tunuguntla AK. Anorectal sensorimotor dysfunction in fecal incontinence and diabetes mellitus. Modification with biofeedback therapy. N Engl J Med. 1984;310(20):1282–7.CrossRefPubMedGoogle Scholar
  79. 79.
    Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;2:CD007959.Google Scholar
  80. 80.
    Tjandra JJ, Chan MK, Yeh CH, Murray-Green C. Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study. Dis Colon Rectum. 2008;51:494–502.CrossRefPubMedGoogle Scholar
  81. 81.
    Gourcerol G, Gallas S, Michot F, Denis P, Leroi AM. Sacral nerve stimulation in fecal incontinence: are there factors associated with success? Dis Colon Rectum. 2007;50:3–12.CrossRefPubMedGoogle Scholar
  82. 82.
    Hetzer FH, Bieler A, Hahnloser D, Löhlein F, Clavien PA, Dematines N. Outcome and cost analysis of sacral nerve stimulation for faecal incontinence. Br J Surg. 2006;93:1411–7.CrossRefPubMedGoogle Scholar
  83. 83.
    Leroi AM, Parc Y, Lehur PA, et al. Efficacy of sacral nerve stimulation for fecal incontinence: results of a multicenter double-blind crossover study. Ann Surg. 2005;242:662–9.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Rosen HR, Urbarz C, Holzer B, Novi G, Schiessel R. Sacral nerve stimulation as a treatment for fecal incontinence. Gastroenterology. 2001;121:536–41.CrossRefPubMedGoogle Scholar
  85. 85.
    Matzel KE, Stadelmaier U, Hohenfellner M, Gall FP. Electrical stimulation of sacral spinal nerves for treatment of faecal incontinence. Lancet. 1995;46:1124–7.CrossRefGoogle Scholar
  86. 86.
    Jarrett ME, Matzel KE, Christiansen J, et al. Sacral nerve stimulation for faecal incontinence in patients with previous partial spinal injury including disc prolapse. Br J Surg. 2005;92:734–9.CrossRefPubMedGoogle Scholar
  87. 87.
    Uludağ O, Koch SM, van Gemert WG, Dejong CH, Baeten CG. Sacral neuromodulation in patients with fecal incontinence: a single-center study. Dis Colon Rectum. 2004;47:1350–7.CrossRefPubMedGoogle Scholar
  88. 88.
    Matzel KE, Kamm MA, Stösser M, et al. Sacral spinal nerve stimulation for faecal incontinence: multicentre study. Lancet. 2004;363:1270–6.CrossRefPubMedGoogle Scholar
  89. 89.
    Malouf AJ, Norton CS, Engel AF, Nicholls RJ, Kamm MA. Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma. Lancet. 2000;355:260–5.CrossRefPubMedGoogle Scholar
  90. 90.
    Madoff RD, Rosen HR, Baeten CG, et al. Safety and efficacy of dynamic muscle plasty for anal incontinence: lessons from a prospective, multicenter trial. Gastroenterology. 1999;116:549–56.CrossRefPubMedGoogle Scholar
  91. 91.
    Rongen MJ, Uludag O, El Naggar K, Gerdes BP, Konsten J, Baeten CG. Long-term follow-up of dynamic graciloplasty for fecal incontinence. Dis Colon Rectum. 2003;46:716–21.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Marinko Marušić
    • 1
    • 2
    • 3
  • Rosana Troskot Perić
    • 1
    • 2
    • 3
  • Nikolina Tolj Karaula
    • 4
  1. 1.Department of Hepatology and GastroenterologyUniversity Hospital Sveti DuhZagrebCroatia
  2. 2.J.J. Strossmayer University of Osijek, Medical SchoolOsijekCroatia
  3. 3.Faculty of Health StudiesUniversity of RijekaRijekaCroatia
  4. 4.Department of Internal MedicineGH Zabok and Croatian Veterans HospitalZabokCroatia

Personalised recommendations